Auxilium boosts urology business with $585M Actient buy

04/30/2013 | Genetic Engineering & Biotechnology News · Reuters

Auxilium Pharmaceuticals agreed to pay $585 million in cash to purchase urology-treatment-maker Actient Holdings. The deal gives Auxilium access to Actient's testosterone replacement therapies and erectile dysfunction drug. The acquisition "creates a leading urology franchise with a diversified product portfolio and sales force leverage that is well positioned for growth of our current portfolio," Auxilium President and CEO Adrian Adams said.

View Full Article in:

Genetic Engineering & Biotechnology News · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Director, Quality Regulatory Affairs
Cardinal Health
Chicago, IL
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC